Decoding 12 Analyst Evaluations For Halozyme Therapeutics
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
解讀奧洛茲美醫療的12項分析師評估
Throughout the last three months, 12 analysts have evaluated Halozyme Therapeutics (NASDAQ:HALO), offering a diverse set of opinions from bullish to bearish.
過去三個月，12位分析師對Halozyme Therapeutics（NASDAQ: HALO）進行了評估，提供了從看漲到看跌的各種觀點。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級概況，突出了過去30天內情緒的變化，並將其與之前的月份進行了比較。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $55.0, a high estimate of $71.00, and a low estimate of $50.00. Witnessing a positive shift, the current average has risen by 1.63% from the previous average price target of $54.12.
分析團隊12個月的價格目標給出了一些觀點，其中包括平均目標價爲55.0美元，最高估值爲71.0美元，最低估值爲50.00美元。當前平均目標價比上一個54.12美元的平均目標價上漲了1.63%。
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
A comprehensive examination of how financial experts...
最近分析師行動...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。